Imreg immunoamplifier research
Executive Summary
Firm is conducting additional trials of its IMREG-1 in approximately 20-25 patients with acquired immune deficiency (AIDS) at the University of Southern California/Los Angeles and Tulane. Investigator Arthur Gottlieb reported at a recent meeting of the American Society of Clinical Investigation that an initial study of five AIDS patients showed IMREG-1 augmented the function of defection immune cells. Previous Imreg immunoamplifier studies in cancer patients have yielded similar results ("The Pink Sheet" April 30, T&G-3).